Apr 24 |
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
Apr 24 |
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
Apr 2 |
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
|
Mar 30 |
10 Best Long Term ASX Stocks To Invest In
|
Mar 19 |
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
|
Mar 11 |
CSL Ltd's Dividend Analysis
|
Mar 6 |
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
|
Feb 25 |
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
|
Feb 23 |
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
|
Feb 13 |
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
|